Back to search
Allergic Bronchopulmonary Aspergillosis (ABPA)
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Allergic Bronchopulmonary Aspergillosis (ABPA) trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Allergic Bronchopulmonary Aspergillosis (ABPA) trials you may qualify forAn open-label study will evaluate effects of Benralizumab in the treatment of severe asthma in patients with allergic bronchopulmonary aspergillosis
To evaluate the efficacy and safety of biological agents in patients with allergic bronchopulmonary aspergillosis.
While ABPA and CPA represent two distinct manifestations of Aspergillus-related lung disease, there is an overlap of investigations that are currently used for…
The goal of this study is to learn how the body's immune system affects disease control in people with different airway inflammatory diseases.We want to underst…
To evaluate the efficacy and safety of bronchoscopic airway clearance and amphotericin B spraying in the treatment of allergic bronchopulmonary aspergillosis
This study is a prospective, observational study of patients aged 18-80 years with clinical diagnosis of bronchial asthma, allergic bronchopulmonary aspergillos…
Asthma is severe when it cannot be controlled with maximum-dose inhaled therapies while management of comorbidities and other precipitating or aggravating facto…
Allergic Bronchopulmonary Aspergillosis is a rare pulmonary disease involving allergic mechanisms, which historically affects patients with asthma or cystic fib…
The primary objective of the study is to evaluate the efficacy of dupilumab on lung function in participants with Allergic Bronchopulmonary Aspergillosis (ABPA)…